Gibco™ Human TGF-beta 2 Recombinant Protein, PeproTech®

Catalog No.	Quantity
10035B100UG	100 μg
10035B10UG	10 μg
10-035-B01M	4 x 250 μg
10-035-B500	2 x 250 μg
10035B250UG	250 μg
100-35B-2UG	2 μg
10035B50UG	50 μg

Catalog No. 10035B100UG Supplier Gibco™ Supplier No. 10035B100UG

Description

Recombinant Protein

100-35B-1MG will be provided as 4 x 250 μg (100-35B-250UG). 100-35B-500UG will be provided as 2 x 250 μg (100-35B-250UG). Recombinant Human TGF-beta2 is a 25.0 kDa protein composed of two identical 112 amino acid polypeptide chains linked by a single disulfide bond. This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis

Transforming Growth Factor (TGF) betas mediate many cell to cell interactions that occur during embryonic development. Three TGF betas have been identified in mammals. TGF beta 1, TGF beta 2 and TGF beta 3 are each synthesized as precursor proteins that are very similar in that each is cleaved to yield a 112 amino acid polypeptide that remains associated with the latent portion of the molecule. The TGF beta polypeptides are multifunctional; capable of influencing cell proliferation, differentiation, and other functions in a wide range of cell types. Transformed, as well as nonneoplastic tissues, release transforming growth factors; and essentially all mammalian cells possess a specific TGF receptor. The multi modal nature of TGF beta is seen in its ability to stimulate or inhibit cellular proliferation. In general, cells of mesenchymal origin appear to be stimulated by TGF beta whereas cells of epithelial or neuroectodermal origin are inhibited by the peptide. TGF beta 1, TGF beta 2, and TGF beta 1.2 appear to be equivalent in biological activity, although there does appear to be differences in binding to certain types of receptors. TGF beta 2 is produced by many cell types and has been found in the highest concentration in porcine platelets and mammalian bone. Latent TGF beta 2 is the prominent isoform found in body fluids such as amniotic fluid, breast milk, and the aqueous and vitreous humor of the eye.

Specifications

• Accession Number: P61812
• For Use With (Application): Control, Bioactivity
• Formulation: Protein with no preservative
• Gene ID (Entrez): 7042
• Molecular Weight (g/mol): 25 kDa
• Name: Human TGF-beta 2
• Purification Method: Purified
• Quantity: 100 μg
• Source: HEK293 cells
• Storage Requirements: -20°C
• Regulatory Status: RUO
• Endotoxin Concentration: <1 EU/μg
• Gene Alias: BB105277; BSC-1 cell growth inhibitor; cetermin; glioblastoma-derived T-cell suppressor factor; G-TSF; LAP; Latency-associated peptide; LDS4; polyergin; prepro-transforming growth factor beta-2; TGF beta 2 protein; TGFB; TGFB2; TGF-B2; Tgfb-2; TGF-beta2; TGF-beta-2; TGFβ2; Transforming growth factor; transforming growth factor beta 2; transforming growth factor beta-2; Transforming growth factor beta-2 proprotein; transforming growth factor, beta 2
• Common Name: TGF beta-2
• Gene Symbol: TGFB2
• Biological Activity: Determined by its ability to inhibit the mouse IL-4-dependent proliferation of mouse HT-2 cells. The ED50 was found to be ≤ 0.2 ng/ml, corresponding to a specific activity of ≥ 5 x 10^6 units/mg
• Product Type: Protein
• Conjugate: Unconjugated
• Recombinant: Recombinant
• Sequence: ALDAAYCFRN VQDNCCLRPL YIDFKRDLGW KWIHEPKGYN ANFCAGACPY LWSSDTQHSR VLSLYNTINP EASASPCCVS QDLEPLTILY YIGKTPKIEQ LSNMIVKSCK CS
• Content And Storage: -20°C
• Activity: Determined by its ability to inhibit the mouse IL-4-dependent proliferation of mouse HT-2 cells. The ED50 was found to be ≤ 0.2 ng/ml, corresponding to a specific activity of ≥ 5 x 10^6 units/mg.
• Expression System: HEK293 cells
• Form: Lyophilized
• Purity or Quality Grade: ≥ 98% by SDS-PAGE gel and HPLC analyses.